Blood clots

First can you tell how old a clot is?  Thern how long does it take to disolve a clot in the right chamber of a enlarged heat 4 times normal size?  The heart also has only a 10% explusion rate or something like that it should normally be 70% from what I was told.
Craig Stevenson


This discussion is related to Dissolving Blood Clots.

[kenkeith]

A  new computer software developed by researchers at the University at Buffalo that simulates clot dissolution using the same techniques employed to analyze chemical reactors will provide information for physicians to know precisely how blood clots, and then tailor drug therapies and reduce patients risks

The computer software is a program that provides a 'snapshot' of a blood clot undergoing dissolution,

By simulating reaction and transport processes at and near the clot, the software provides critical information about the function of tissue plasminogen-activator (tPA) and other thrombolytic agents used to dissolve blood clots in coronary arteries and elsewhere in the body.

The goal, as post suggests, is to dissolve the clot and re-establish flow through the blood vessels as quickly as possible.  If you use too much drug, you risk bleeding complications. If you use too little, you don't dissolve the clot. It can be very difficult to predict how best to use these thrombolytic agents for each patient. So I don't know if there is an answer to specific variables stated in your post.

In addition, many variables, such as the type of clot, its age, where it is located and the initial disease that caused it, can affect the safety and efficacy of the treatment for an individual.

The software program takes the biochemistry and clot structure into account, and based on specific drug concentrations and methods of administration, it calculates what happens when the drug is administered, how quickly the clot dissolves and the chances of it suddenly breaking apart, which is hazardous.

The model predicts how the blood chemistry is changing in real-time in response to what the clinician is doing, based on any thrombolytic agent used or infusion regimen.  There never has been a predicition with these dynamics and outcomes before. For that reason, it is expected to help streamline the design of clinical trials for new, clot-dissolving drugs.